Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 7/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.45 |
| ▸ | EDNRA | P25101 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.44 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28194454 | 0.83 | ACHE (0.50) | ACHECA1CA2CA7CA9 | |
| SCHEMBL1603871 | 0.83 | ACHE (0.50) | ACHECA1CA2CA7CA9 | |
| SCHEMBL31425668 | 0.82 | ACHE (0.54) | ACHECA1CA2CA7CA9 | |
| SCHEMBL1157811 | 0.82 | ACHE (0.54) | ACHECA1CA2CA7CA9 | |
| SCHEMBL3164341 | 0.82 | ACHE (0.54) | ACHECA1CA2CA7CA9 | |
| SCHEMBL24433577 | 0.80 | ACHE (0.52) | ACHECA1CA2CA7CA9 | |
| SCHEMBL29974516 | 0.80 | CYP1A2 (0.58) | ACHECA1CA2CA7CA9 | |
| SCHEMBL1145531 | 0.80 | CYP1A2 (0.58) | ACHECA1CA2CA7CA9 | |
| SCHEMBL14032765 | 0.79 | PARP1 (0.47) | ACHECA1CA2CA7CA9 | |
| SCHEMBL7059306 | 0.78 | ACHE (0.56) | ACHECA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 313 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115651170-A | Preparation of heptazine-based polymer and application of heptazine-based polymer in photocatalytic oxidation of thioether | 福州大学 | 2023-01-31 | — | — | CN | claimed |
| EP-3325443-B1 | PROCESS FOR PREPARING PRIDOPIDINE | Prilenia Neurotherapeutics Ltd (IL) | 2022-06-08 | — | — | EP | claimed |
| CN-113511997-A | Pridopidine analogues, their preparation and use | 普丽莱尼亚神经治疗有限公司 | 2021-10-19 | — | — | CN | claimed |
| US-10406145-B2 | Analogs of pridopidine, their preparation and use | PRILENIA NEUROTHERAPEUTICS LTD. (IL) | 2019-09-10 | — | — | US | claimed |
| US-20190030016-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2019-01-31 | — | — | US | claimed |
| EP-3325443-A1 | PROCESS FOR PREPARING PRIDOPIDINE | Teva Pharmaceuticals International GmbH (CH) | 2018-05-30 | — | — | EP | claimed |
| EP-3160470-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | Teva Pharmaceutical Industries Ltd (IL) | 2017-05-03 | — | — | EP | claimed |
| WO-2017015609-A1 | PROCESS FOR PREPARING PRIDOPIDINE | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2017-01-26 | — | — | WO | claimed |
| US-20170022158-A1 | PROCESS FOR PREPARING PRIDOPIDINE | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2017-01-26 | — | — | US | claimed |
| WO-2016003919-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2016-01-07 | — | — | WO | claimed |
| US-20250382406-A1 | CURABLE COMPOSITION, CURED PRODUCT, OPTICAL MATERIAL, DIFFRACTIVE OPTICAL ELEMENT, AND COMPOUND | FUJIFILM CORPORATION (JP) | 2025-12-18 | — | — | US | disclosed |
| EP-4660207-A1 | CURABLE COMPOSITION, CURED PRODUCT, OPTICAL MATERIAL, DIFFRACTIVE OPTICAL ELEMENT, AND COMPOUND | FUJIFILM Corporation (JP) | 2025-12-10 | — | — | EP | disclosed |
| US-20250277072-A1 | CURABLE COMPOSITION, CURED PRODUCT, OPTICAL MATERIAL, DIFFRACTIVE OPTICAL ELEMENT, AND MONOFUNCTIONAL (METH)ACRYLIC ACID THIOESTER MONOMER | FUJIFILM CORPORATION (JP) | 2025-09-04 | — | — | US | disclosed |
| EP-4565586-A1 | NOVEL ECTONUCLEOTIDE PYROPHOSPHATASE / PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | Sravathi Ai Technology Private Limited (IN) | 2025-06-11 | — | — | EP | disclosed |
| CN-119677742-A | Novel external nucleotide pyrophosphatase/phosphodiesterase 1 (ENPP 1) inhibitor and application thereof | 斯拉瓦蒂人工智能科技私人有限公司 | 2025-03-21 | — | — | CN | disclosed |
| US-5130316-A | Arylbenzene oxazolidinone compounds | DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-07-14 | — | — | US | disclosed |
| US-5043443-A | Bactericides | DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1991-08-27 | — | — | US | disclosed |
| US-4948801-A | Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-08-14 | — | — | US | disclosed |
| US-4900725-A | CONTRACEPTIVES | ROUSSEL UCLAF (FR) | 1990-02-13 | — | — | US | disclosed |
| EP-0252639-A1 | Leukotriene antagonists | MERCK FROSST CANADA INC. (CA) | 1988-01-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10406145-B2 | Analogs of pridopidine, their preparation and use | QDPR, DRD2, OPRD1 | ACHE 2752/4885CA1 4389/4885CA2 2324/4885 |
| US-20170022158-A1 | PROCESS FOR PREPARING PRIDOPIDINE | PDE6D, QDPR, PDE4D | ACHE 4017/4885CA1 4777/4885CA2 4397/4885 |
| US-20250382406-A1 | CURABLE COMPOSITION, CURED PRODUCT, OPTICAL MATERIAL, DIFFRACTIVE OPTICAL ELEMENT, AND COMPOUND | C5, Q6ZSR9, C9 | ACHE 1073/4885CA1 1465/4885CA2 3634/4885 |
| US-20250277072-A1 | CURABLE COMPOSITION, CURED PRODUCT, OPTICAL MATERIAL, DIFFRACTIVE OPTICAL ELEMENT, AND MONOFUNCTIONAL (METH)ACRYLIC ACID THIOESTER MONOMER | CAD, ADCY1, AMD1 | ACHE 1694/4885CA1 1180/4885CA2 4225/4885 |
| US-20190030016-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | QDPR, DRD2, OPRD1 | ACHE 2752/4885CA1 4389/4885CA2 2324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.